<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949960</url>
  </required_header>
  <id_info>
    <org_study_id>DMT210-002</org_study_id>
    <nct_id>NCT02949960</nct_id>
  </id_info>
  <brief_title>DMT210 Topical Gel in the Treatment of Atopic Dermatitis</brief_title>
  <official_title>DMT210 Topical Gel in the Treatment of Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermata Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermata Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of DMT210 Gel, 5% compared
      to vehicle control following 28 days of twice-daily topical application to selected target
      lesions in male and female patients with mild to moderate atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">July 14, 2017</completion_date>
  <primary_completion_date type="Actual">July 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADSI (Atopic Dermatitis Severity Index) score of each Target lesion</measure>
    <time_frame>Day 28</time_frame>
    <description>Change from baseline in ADSI score between Vehicle and 5% gel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Individual Signs and Symptoms of Atopic Dermatitis of each Target Lesion</measure>
    <time_frame>Day 28</time_frame>
    <description>Change from baseline in AD symptom scores between Vehicle and 5% gel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment (IGA) of the Treatment Area</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events as a measure of safety and tolerability</measure>
    <time_frame>Day 28</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>DMT210 Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DMT210 Topical Gel 5% applied to target lesion twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical Gel vehicle applied to target lesion twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMT210 Topical Gel</intervention_name>
    <description>DMT210 Topical Aqueous Gel 5% applied twice daily</description>
    <arm_group_label>DMT210 Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Control</intervention_name>
    <description>Topical Vehicle Gel applied twice daily</description>
    <arm_group_label>Vehicle Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 12 years or older

          -  Patient has chronic, stable AD that has been present for at least 3 months with 5-35%
             (inclusive) BSA (Body Surface Area) of AD involvement

          -  Patient has two analogous, Target Lesions; one lesion within each of the two Treatment
             Areas

          -  Patient is willing and able to comply with the protocol

        Exclusion Criteria:

          -  Patient has used topical therapies for AD within the Treatment Areas 2 weeks before
             baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Nardo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dermata Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermata Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eczema</keyword>
  <keyword>Dermatitis</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Skin Diseases, Genetic</keyword>
  <keyword>Dermatitis, Atopic</keyword>
  <keyword>Skin Diseases, Eczematous</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Immune System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

